A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

Summary

Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG). This study aims to evaluate whether the titration mode of administration could reduce the incidence of adverse reactions of PEX168, also decided to observe long-term continuous administration of PK/PD correlation.

Timeline

Start

2012-03

Primary completion

2013-03

Completion

2013-04

Drugs

Indications